ArriVent BioPharma, Inc. financial statements
ArriVent BioPharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2025
| Net income | −USD 166.31M | 10-K |
| Cash and equivalents | USD 45.54M | 10-Q |
ArriVent BioPharma, Inc. financials on 6ix · ArriVent BioPharma, Inc. on 6ix